Dr. Reddy's Launches BixiBat (Elobixibat) for Chronic Constipation in India
核心洞察
Dr. Reddy's Laboratories has launched BixiBat (搜索), containing elobixibat, in India as a novel treatment for chronic constipation (搜索).
The drug's approval by the CDSCO was based on successful Phase-3 clinical trial data submitted by Dr. Reddy's.
Elobixibat inhibits bile acid reabsorption in the ileum, increasing colonic fluid secretion and motility to promote bowel movements.
Dr. Reddy's Laboratories has announced the launch of BixiBat (搜索), a drug containing elobixibat, in India for the treatment of chronic constipation (搜索). This launch follows the approval granted by the Central Drugs Standard Control Organisation (CDSCO) after reviewing Dr. Reddy's successful Phase-3 clinical trial data.
Dr. Reddy's is the first company to receive approval for and launch elobixibat in India. Elobixibat represents a new class of drugs designed to address chronic constipation (搜索) by targeting bile acid reabsorption.
Mechanism of Action
Elobixibat functions by inhibiting the reabsorption of bile acids (搜索) in the ileum. This inhibition increases the concentration of bile acids in the colonic lumen, which stimulates both colonic motility and fluid secretion. The increased fluid secretion and motility lead to more frequent bowel movements, irrespective of transit speed.